Group 1 - The company has signed a share and asset purchase agreement with Kirin Holdings' subsidiary to acquire certain businesses for 10.5 billion JPY (approximately 500 million CNY) [1] - The acquisition includes food amino acids, pharmaceutical amino acids, and human milk oligosaccharides (HMO) [1] - The final transaction price is approximately 16.8 billion JPY (about 833 million CNY) after adjustments based on cash reserves and working capital [2] Group 2 - The business transfer was completed on July 1, 2025, with all conditions of the agreement met [2] - As of June 30, 2025, the estimated cash on hand for the acquired assets was approximately 11.3 billion JPY (about 560 million CNY) [2] - The company will continue to monitor the progress of the acquisition and provide timely updates as required [2]

证券代码：600873 证券简称：梅花生物 公告编号：2025-043 梅花生物科技集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 重要内容提示： 一、回购股份的基本情况 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2024 年 9 月 23 日、2024 年 10 月 11 日召开了公司第十届董事会第十三次会议和 2024 年第二次临 时股东大会，会上审议通过了《关于以集中竞价交易方式回购公司股份的议案》。 公司于 2024 年 10 月 12 日披露了《梅花生物科技集团股份有限公司关于以集中竞 价交易方式回购股份的回购报告书》，本次回购金额不低于人民币 3 亿元，不超过 人民币 5 亿元，回购 ...

证券代码：600873 证券简称：梅花生物 公告编号：2025-045 1.因交易涉及多个国内外生产经营实体的股权变更，相关变更手续尚在办理 中。 2.公司已聘请专业机构对标的资产开展审计、评估工作，本次交易对公司 2025 年业绩影响将参考审计、评估结果确定。 经公司第十届董事会第十六次会议审议通过，2024 年 11 月 22 日，公司及 全资子公司 PLUM BIOTECHNOLOGY GROUP PTE.LTD.（简称"新加坡公司"） 与 Kirin Holdings Company, Limited（简称"麒麟控股"，东京证券交易所上市公 司，股票代码 2503.T）的全资子公司 Kyowa Hakko Bio Co., Ltd.（协和发酵株式 会社，简称"协和发酵"）签署了《股份及资产购买协议》，新加坡公司或新加坡 公司下新设的特殊目的实体（"SPV"）拟以 105 亿日元（以当日汇率折合人民币 约 5 亿元）现金收购协和发酵旗下食品氨基酸、医药氨基酸及母乳低聚糖（HMO） 业务（统称"标的资产"），具体内容详见公司披露的相关公告。 二、交易进展 依据《股份及资产购买协议》及相关补充协议约定，协议 ...

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2025 年 2 月 11 日、2025 年 2 月 27 日召开第十届董事会第十七次会议和 2025 年第一次临时 股东大会，审议通过《关于公司 2025 年员工持股计划（草案）及其摘要的议案》 《关于公司 2025 年员工持股计划管理办法的议案》《关于提请股东大会授权董事 会全权办理公司员工持股计划相关事项的议案》，具体内容详见公司于 2025 年 2 月 12 日、2025 年 2 月 28 日在上海证券交易所网站（http://www.sse.com.cn）上 披露的相关公告。 证券代码：600873 证券简称：梅花生物 公告编号：2025-044 梅花生物科技集团股份有限公司 关于2025年员工持股计划实施进展的公告 截至 2025 年 6 月底，公司 2025 年员工持股计划专户已通过二级市场以集中 竞 价 交 易 方 式 累 计 买 入 公 司 股 份 16,083,051 股 ， 占 公 司 目 前 股 ...

Investment Rating - The report assigns a "Strong Buy" rating to the company with a target price of 13.20 CNY, compared to the current price of 10.76 CNY [1][12]. Core Views - The company focuses on the amino acid industry and aims to become a leader in synthetic biology, leveraging its extensive experience and capabilities in the sector [5][16]. - The company has established a strong market position in various segments, including animal nutrition amino acids, flavor enhancers, human medical amino acids, and colloidal polysaccharides, with significant production capacities [5][9]. - The acquisition of Xiehe Fermentation is expected to enhance the company's product portfolio and accelerate its international expansion strategy [10][11]. Summary by Sections 1. Focus on Amino Acid Core Business - The company has been deeply engaged in the amino acid industry for years, establishing a leading position with production bases in Jilin, Inner Mongolia, and Xinjiang [5][16]. - Current production capacities include 1.1 million tons/year for MSG, 1 million tons/year for lysine, and 450,000 tons/year for threonine, with plans for further expansion [5][25]. 2. Steady Demand Growth and Competitive Advantage - The demand for animal nutrition amino acids is steadily increasing, driven by rising consumer income and the need for high-quality animal protein [5][9]. - The company benefits from a strong competitive position, with a high concentration in the threonine industry and a significant market share in lysine [5][9]. 3. Acquisition and International Expansion - The planned acquisition of Xiehe Fermentation is expected to enhance the company's capabilities in pharmaceutical amino acids and facilitate its international market entry [10][11]. - This acquisition will allow the company to optimize its product structure and strengthen its risk resistance in the global market [10][11]. 4. Financial Performance and Shareholder Returns - The company has maintained a strong cash flow, with cumulative cash dividends of 11.51 billion CNY from 2012 to 2024 and a dividend payout ratio of 62% in 2024 [10][11]. - The report forecasts revenue growth from 27.24 billion CNY in 2025 to 32.78 billion CNY in 2027, with corresponding net profits increasing from 3.14 billion CNY to 3.86 billion CNY [12][7].

Core Viewpoint - MeiHua Bio's performance in 2024 showed a decline in revenue and net profit, but the first quarter of 2025 demonstrated strong profit growth, indicating a potential recovery and growth trajectory driven by new projects and international expansion [2][3]. Financial Performance - In 2024, MeiHua Bio achieved a total revenue of 25.069 billion yuan, a decrease of 9.69% year-on-year; net profit attributable to shareholders was 2.740 billion yuan, down 13.85% year-on-year; and net profit excluding non-recurring items was 2.697 billion yuan, down 12.55% year-on-year [2]. - For Q1 2025, the company reported revenue of 6.269 billion yuan, a year-on-year decrease of 3.36% and a quarter-on-quarter decrease of 1.88%; however, net profit attributable to shareholders increased by 35.52% year-on-year to 1.019 billion yuan, with a quarter-on-quarter increase of 36.72% [2]. - The growth in Q1 2025 net profit was attributed to increased sales of products such as monosodium glutamate and threonine, along with a decrease in material costs and improved production efficiency [2]. Growth Drivers - The company is expanding production capacity for key products, with successful completion of the Tongliao monosodium glutamate expansion project and planned production for several other projects in 2024 [2]. - Research and development investment reached 733 million yuan, focusing on basic research and the promotion of new technologies and strains [2]. - MeiHua Bio is pursuing international expansion, planning to invest approximately 500 million yuan to acquire assets related to amino acids and HMO business from Xiehe Fermentation [2]. Profit Forecast and Investment Recommendation - The company is expected to see net profits of 3.144 billion yuan, 3.367 billion yuan, and 3.745 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.10, 1.18, and 1.31 yuan [3]. - Current stock price corresponds to PE ratios of 9.69, 9.05, and 8.13 for the same years, maintaining a "buy" investment rating [3].

Investment Rating - The report maintains a "Buy" investment rating for the company, indicating a positive outlook for its stock performance relative to the market [6][7]. Core Insights - The company reported a revenue of 250.69 billion yuan for 2024, a decrease of 9.69% year-on-year, and a net profit attributable to shareholders of 27.40 billion yuan, down 13.85% year-on-year. However, the first quarter of 2025 showed a net profit increase of 35.52% year-on-year, driven by higher sales volumes of key products [7]. - The company is expanding its production capacity and enhancing its international presence, with significant investments in R&D amounting to 733 million yuan, focusing on basic research and new technologies [7]. - The projected net profits for 2025, 2026, and 2027 are 31.44 billion yuan, 33.67 billion yuan, and 37.45 billion yuan, respectively, with corresponding EPS of 1.10, 1.18, and 1.31 yuan [7][8]. Company Overview - The latest closing price of the company's stock is 10.68 yuan, with a total market capitalization of 305 billion yuan. The company has a debt-to-asset ratio of 38.8% and a price-to-earnings ratio of 11.36 [3][4]. Financial Forecasts - The company is expected to see a revenue increase in the coming years, with projected revenues of 272 billion yuan in 2025, 302 billion yuan in 2026, and 321 billion yuan in 2027, reflecting growth rates of 8.32%, 11.16%, and 6.45%, respectively [8][9]. - The EBITDA is forecasted to grow from 46.92 billion yuan in 2024 to 58.90 billion yuan in 2027, indicating improving operational efficiency [8].

Investment Rating - The report maintains a "Buy" rating for several companies in the chemical industry, including Sinopec, PetroChina, and CNOOC, highlighting their high dividend characteristics [10]. Core Views - The report emphasizes the importance of focusing on domestic demand, high dividend stocks, and import substitution in the chemical industry, especially in light of the recent stabilization of international oil prices [6][17]. - It notes that the international oil price is expected to stabilize around $70 per barrel in 2025, which supports the outlook for companies with strong asset quality and high dividend yields [6][17]. Summary by Sections Industry Investment Recommendations - The report suggests that the chemical industry is currently in a weak performance phase, with mixed results across different sub-sectors due to past capacity expansions and weak demand [20]. - It highlights specific sectors such as the tire industry, which is expected to perform well due to global positioning and tariff experiences [20]. - The report also identifies opportunities in import substitution for chemical products like lubricant additives and special coatings [20]. Price Movements - Significant price increases were observed in natural gas (up 14.76%), hydrochloric acid (up 9.39%), and synthetic ammonia (up 5.24%) [17][18]. - Conversely, products like adipic acid and coal tar saw notable declines, with adipic acid down 7.53% [17][18]. Key Companies and Earnings Forecasts - The report provides earnings per share (EPS) forecasts for various companies, indicating a positive outlook for firms like Xinyangfeng and Senqilin, with projected EPS growth [10]. - It lists several companies with strong dividend yields, such as Yuntianhua and Xingfa Group, which are expected to attract investor interest [20].

一、回购股份的基本情况 证券代码：600873 证券简称：梅花生物 公告编号：2025-041 梅花生物科技集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/9/24，由公司董事长王爱军提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 10 | 10 | 月 | 11 | 日~2025 | 年 | 10 | 日 | | 预计回购金额 | 30,000万元~50,000万元 | | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 3,570.84万股 | | | | | | | | | 累计已回购股数占总股本比例 | 1.25% | | | | ...

证券代码：600873 证券简称：梅花生物 公告编号：2025-042 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》及《上 海证券交易所上市公司自律监管指引第 1 号—规范运作》等要求，现将公司 2025 年员工持股计划实施进展情况公告如下： 截至 2025 年 5 月底，公司 2025 年员工持股计划专户已通过二级市场以集中 竞 价 交 易 方 式 累 计 买 入 公 司 股 份 8,527,700 股 ， 占 公 司 目 前 股 本 总 数 （2,852,788,750 股）的 0.30%，成交均价 10.55 元/股，成交金额 89,962,022 元（不 含交易费用）。 公司 2025 年员工持股计划尚未实施完毕，后续公司将持续关注本次员工持 股计划的实施进展情况，并按照相关法律、行政法规的规定及时履行信息披露义 务。敬请广大投资者关注相关公告并注意投资风险。 关于2025年员工持股计划实施进展的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分 ...